Pergolide mesylate (BioDeep_00000399152)

   

natural product


代谢物信息卡片


Pergolide mesylate salt

化学式: C20H30N2O3S2 (410.169775)
中文名称: 甲磺酸培高利特
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: C12(C3[C@@]4([C@@](CC1=CNC=2C=CC=3)(N(C[C@H](C4)CSC)CCC)[H])[H]).CS(O)(=O)=O
InChI: /m1./s1

描述信息

D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists
C78272 - Agent Affecting Nervous System > C38149 - Antiparkinsonian Agent
C78272 - Agent Affecting Nervous System > C66884 - Dopamine Agonist
Pergolide mesylate (Pergolide methanesulfonate), an Ergoline derivative, is a potent and orally active dopamine D1 and D2 receptors agonist. Pergolide mesylate can be used for Parkinson's disease and hyperprolactinaemia research[1][2].

同义名列表

5 个代谢物同义名

Pergolide mesylate salt; Pergolide mesylate; Pergolide methanesulfonate; LY127809; Pergolide (mesylate)



数据库引用编号

10 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • A B Miller, A T Loynachan, H M Bush, K A Hart, V D Barker, A G Campana-Emard, S T Grubbs, A A Adams. Effects of pituitary pars intermedia dysfunction and Prascend (pergolide tablets) treatment on endocrine and immune function in horses. Domestic animal endocrinology. 2021 01; 74(?):106531. doi: 10.1016/j.domaniend.2020.106531. [PMID: 32942194]
  • R C Tatum, C M McGowan, J L Ireland. Efficacy of pergolide for the management of equine pituitary pars intermedia dysfunction: A systematic review. Veterinary journal (London, England : 1997). 2020 Dec; 266(?):105562. doi: 10.1016/j.tvjl.2020.105562. [PMID: 33323174]
  • D I Rendle, G Doran, J Ireland, S Edwards. Pharmacokinetics and pharmacodynamics of pergolide mesylate after oral administration in horses with pituitary pars intermedia dysfunction. Domestic animal endocrinology. 2019 07; 68(?):135-141. doi: 10.1016/j.domaniend.2019.01.008. [PMID: 31082785]
  • Garance Christen, Vinzenz Gerber, Johannes Hermanus van der Kolk, Caroline Franziska Frey, Nathalie Fouché. Fecal strongyle egg counts in horses with suspected pre-clinical pituitary pars intermedia dysfunction before and after treatment with pergolide. Veterinary journal (London, England : 1997). 2018 05; 235(?):60-62. doi: 10.1016/j.tvjl.2018.03.007. [PMID: 29704940]
  • D McFarlane, H Banse, H K Knych, L K Maxwell. Pharmacokinetic and pharmacodynamic properties of pergolide mesylate following long-term administration to horses with pituitary pars intermedia dysfunction. Journal of veterinary pharmacology and therapeutics. 2017 Apr; 40(2):158-164. doi: 10.1111/jvp.12339. [PMID: 27301465]
  • David I Rendle, Kris J Hughes, Gregory S Doran, Scott H Edwards. Pharmacokinetics of pergolide after intravenous administration to horses. American journal of veterinary research. 2015 Feb; 76(2):155-60. doi: 10.2460/ajvr.76.2.155. [PMID: 25629913]
  • Glenn A Jacobson, Adam Pirie, Scott Edwards, Kristopher J Hughes, David I Rendle, Noel W Davies. Determination of pergolide in horse plasma by UPLC-MS/MS for pharmacokinetic applications. Journal of pharmaceutical and biomedical analysis. 2014 Jun; 94(?):54-7. doi: 10.1016/j.jpba.2014.01.016. [PMID: 24549007]
  • Gregory Doran, Kristopher Hughes, David Rendle, Scott Edwards. The analysis of pergolide residues in horse plasma by LC with fluorescence detection. Journal of AOAC International. 2013 Nov; 96(6):1487-93. doi: 10.5740/jaoacint.12-282. [PMID: 24645533]
  • Lucian Hritcu, Alin Ciobica. Intranigral lipopolysaccharide administration induced behavioral deficits and oxidative stress damage in laboratory rats: relevance for Parkinson's disease. Behavioural brain research. 2013 Sep; 253(?):25-31. doi: 10.1016/j.bbr.2013.07.006. [PMID: 23850357]
  • Alin Ciobica, Zenovia Olteanu, Manuela Padurariu, Lucian Hritcu. The effects of pergolide on memory and oxidative stress in a rat model of Parkinson's disease. Journal of physiology and biochemistry. 2012 Mar; 68(1):59-69. doi: 10.1007/s13105-011-0119-x. [PMID: 22006204]
  • Kamal S Bhatia, Steven T Szabo, J Corey Fowler, William C Wetsel, Tong H Lee. Reversal of long-term methamphetamine sensitization by combination of pergolide with ondansetron or ketanserin, but not mirtazapine. Behavioural brain research. 2011 Sep; 223(1):227-32. doi: 10.1016/j.bbr.2011.04.045. [PMID: 21571009]
  • Yasuto Kido, Pär Matsson, Kathleen M Giacomini. Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. Journal of medicinal chemistry. 2011 Jul; 54(13):4548-58. doi: 10.1021/jm2001629. [PMID: 21599003]
  • Motomi Arai. Increased plasma arginine vasopressin levels in dopamine agonist-treated Parkinson's disease patients. Neuro endocrinology letters. 2011; 32(1):39-43. doi: . [PMID: 21407160]
  • Ronette Gehring, Laurie Beard, Abra Wright, Johann Coetzee, James Havel, Michael Apley. Single-dose oral pharmacokinetics of pergolide mesylate in healthy adult mares. Veterinary therapeutics : research in applied veterinary medicine. 2010; 11(1):E1-8. doi: . [PMID: 20949429]
  • Shin-ichi Ono, Kohji Hirai, Ei-ichi Tokuda. Effects of pergolide mesilate on metallothionein mRNAs expression in a mouse model for Parkinson disease. Biological & pharmaceutical bulletin. 2009 Oct; 32(10):1813-7. doi: 10.1248/bpb.32.1813. [PMID: 19801850]
  • Sanjeev Bhattacharyya, Anthony H Schapira, Dimitri P Mikhailidis, Joseph Davar. Drug-induced fibrotic valvular heart disease. Lancet (London, England). 2009 Aug; 374(9689):577-85. doi: 10.1016/s0140-6736(09)60252-x. [PMID: 19683643]
  • Hideki Ohno, Masashi Nakajima, Shinsuke Fujioka, Kohnosuke Iwamoto, Mitsuru Kawamura. Overnight switching from ergot-derived dopamine agonists to pramipexole in patients with Parkinson's disease: an open preliminary trial in Japan. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. 2009 Jun; 16(6):790-2. doi: 10.1016/j.jocn.2008.09.001. [PMID: 19286385]
  • Michal Pohanka, Petr Kanovský, Martin Bares, Jiri Pulkrábek, Ivan Rektor. The long-lasting improvement of sexual dysfunction in patients with advanced, fluctuating Parkinson's disease induced by pergolide: evidence from the results of an open, prospective, one-year trial. Parkinsonism & related disorders. 2005 Dec; 11(8):509-12. doi: 10.1016/j.parkreldis.2005.03.004. [PMID: 15994112]
  • F Galluzzi, R Salti, S Stagi, F La Cauza, F Chiarelli. Reversible weight gain and prolactin levels--long-term follow-up in childhood. Journal of pediatric endocrinology & metabolism : JPEM. 2005 09; 18(9):921-4. doi: 10.1515/jpem.2005.18.9.921. [PMID: 16279371]
  • Claire Thalamas, Iris Rajman, Jaime Kulisevsky, Alberto Lledó, Alison E Mackie, Olivier Blin, Todd A Gillespie, Mary Seger, Olivier Rascol. Pergolide: multiple-dose pharmacokinetics in patients with mild to moderate Parkinson disease. Clinical neuropharmacology. 2005 May; 28(3):120-5. doi: 10.1097/01.wnf.0000168581.97083.9c. [PMID: 15965310]
  • G R A Focchi, M C Leite, A G Andrade, S Scivoletto. Use of dopamine agonist pergolide in outpatient treatment of cocaine dependence. Substance use & misuse. 2005; 40(8):1169-77. doi: 10.1081/ja-200030552. [PMID: 16040376]
  • M Chalimoniuk, A Stepień. Influence of the therapy with pergolide mesylate plus L-DOPA and with L-DOPA alone on serum cGMP level in PD patients. Polish journal of pharmacology. 2004 Sep; 56(5):647-50. doi: NULL. [PMID: 15591656]
  • Malgorzata Chalimoniuk, A Stepień, J B Strosznajder. Pergolide mesylate, a dopaminergic receptor agonist, applied with L-DOPA enhances serum antioxidant enzyme activity in Parkinson disease. Clinical neuropharmacology. 2004 Sep; 27(5):223-9. doi: 10.1097/01.wnf.0000145509.84389.ce. [PMID: 15602103]
  • M Pohanka, P Kanovský, M Bares, J Pulkrábek, I Rektor. Pergolide mesylate can improve sexual dysfunction in patients with Parkinson's disease: the results of an open, prospective, 6-month follow-up. European journal of neurology. 2004 Jul; 11(7):483-8. doi: 10.1111/j.1468-1331.2004.00820.x. [PMID: 15257688]
  • Serhat Ozkan, Omer Colak, Ceyhan Kutlu, Melek Ertan, Ozkan Alatas. Plasma homocysteine levels in pergolide-treated Parkinson disease patients. Clinical neuropharmacology. 2004 Jul; 27(4):163-5. doi: 10.1097/01.wnf.0000136890.78887.b9. [PMID: 15319701]
  • Olivier Blin. The pharmacokinetics of pergolide in Parkinson's disease. Current opinion in neurology. 2003 Dec; 16 Suppl 1(?):S9-12. doi: 10.1097/00019052-200312001-00003. [PMID: 15180132]
  • Nicola Hughes, Witold Winnik, Jean-Jacques Dunyach, Ma'an Amad, Maurizio Splendore, Gary Paul. High-sensitivity quantitation of cabergoline and pergolide using a triple-quadrupole mass spectrometer with enhanced mass-resolution capabilities. Journal of mass spectrometry : JMS. 2003 Jul; 38(7):743-51. doi: 10.1002/jms.489. [PMID: 12898654]
  • Himanshu P Upadhyaya, Kathleen T Brady, Jason Liao, Gopalan Sethuraman, Larry Middaugh, Mollie Wharton, Floyd R Sallee. Neuroendocrine and behavioral responses to dopaminergic agonists in adolescents with alcohol abuse. Psychopharmacology. 2003 Mar; 166(2):95-101. doi: 10.1007/s00213-002-1303-z. [PMID: 12520313]
  • Joan Santamaria, Alex Iranzo, Eduard Tolosa. Development of restless legs syndrome after dopaminergic treatment in a patient with periodic leg movements in sleep. Sleep medicine. 2003 Mar; 4(2):153-5. doi: 10.1016/s1389-9457(02)00153-3. [PMID: 14592347]
  • Patrick Santens. Sleep attacks in Parkinson's disease induced by Entacapone, a COMT-inhibitor. Fundamental & clinical pharmacology. 2003 Feb; 17(1):121-3. doi: 10.1046/j.1472-8206.2003.00121.x. [PMID: 12588639]
  • Johan Verhelst, Roger Abs. Hyperprolactinemia: pathophysiology and management. Treatments in endocrinology. 2003; 2(1):23-32. doi: 10.2165/00024677-200302010-00003. [PMID: 15871552]
  • Mark T Donaldson, Bernadette H LaMonte, Peter Morresey, Gary Smith, Jill Beech. Treatment with pergolide or cyproheptadine of pituitary pars intermedia dysfunction (equine Cushing's disease). Journal of veterinary internal medicine. 2002 Nov; 16(6):742-6. doi: 10.1892/0891-6640(2002)016<0742:twpoco>2.3.co;2. [PMID: 12465775]
  • G A Perkins, S Lamb, H N Erb, B Schanbacher, D V Nydam, T J Divers. Plasma adrenocorticotropin (ACTH) concentrations and clinical response in horses treated for equine Cushing's disease with cyproheptadine or pergolide. Equine veterinary journal. 2002 Nov; 34(7):679-85. doi: 10.2746/042516402776250333. [PMID: 12455838]
  • S K Hemrick-Luecke, F P Bymaster, D C Evans, J Wess, C C Felder. Muscarinic agonist-mediated increases in serum corticosterone levels are abolished in m(2) muscarinic acetylcholine receptor knockout mice. The Journal of pharmacology and experimental therapeutics. 2002 Oct; 303(1):99-103. doi: 10.1124/jpet.102.036020. [PMID: 12235238]
  • Mohammad A Newaz, Zivar Yousefipour, Adebayo Oyekan. Effects of pergolide on blood pressure and tissue injury in DOCA-salt hypertension. Blood pressure. 2002; 11(2):110-5. doi: 10.1080/08037050211266. [PMID: 12035871]
  • A Chiarenza, M Scarselli, F Novi, L Lempereur, R Bernardini, G U Corsini, R Maggio. Apomorphine, dopamine and phenylethylamine reduce the proportion of phosphorylated insulin receptor substrate 1. European journal of pharmacology. 2001 Dec; 433(1):47-54. doi: 10.1016/s0014-2999(01)01491-1. [PMID: 11755133]
  • W Koller, A Lees, M Doder, M Hely. Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations. Movement disorders : official journal of the Movement Disorder Society. 2001 Sep; 16(5):858-66. doi: 10.1002/mds.1175. [PMID: 11746615]
  • R Malcolm, D K Kajdasz, J Herron, R F Anton, K T Brady. A double-blind, placebo-controlled outpatient trial of pergolide for cocaine dependence. Drug and alcohol dependence. 2000 Aug; 60(2):161-8. doi: 10.1016/s0376-8716(99)00151-9. [PMID: 10940543]
  • M Scarselli, M Armogida, S Chiacchio, M G DeMontis, A Colzi, G U Corsini, R Maggio. Reconstitution of functional dopamine D(2s) receptor by co-expression of amino- and carboxyl-terminal receptor fragments. European journal of pharmacology. 2000 Jun; 397(2-3):291-6. doi: 10.1016/s0014-2999(00)00272-7. [PMID: 10844126]
  • Y Ihara, M Chuda, S Kuroda, T Hayabara. Hydroxyl radical and superoxide dismutase in blood of patients with Parkinson's disease: relationship to clinical data. Journal of the neurological sciences. 1999 Nov; 170(2):90-5. doi: 10.1016/s0022-510x(99)00192-6. [PMID: 10561523]
  • J E Ahlskog, R J Uitti, M K O'Connor, D M Maraganore, J Y Matsumoto, K F Stark, M F Turk, O L Burnett. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. 1999 Nov; 14(6):940-6. doi: 10.1002/1531-8257(199911)14:6<940::aid-mds1005>3.0.co;2-y. [PMID: 10584667]
  • M Gómez-Vargas, S Nishibayashi-Asanuma, M Asanuma, Y Kondo, E Iwata, N Ogawa. Pergolide scavenges both hydroxyl and nitric oxide free radicals in vitro and inhibits lipid peroxidation in different regions of the rat brain. Brain research. 1998 Apr; 790(1-2):202-8. doi: 10.1016/s0006-8993(97)01521-7. [PMID: 9593894]
  • A L Barkan, W F Chandler. Giant pituitary prolactinoma with falsely low serum prolactin: the pitfall of the 'high-dose hook effect': case report. Neurosurgery. 1998 Apr; 42(4):913-5; discussion 915. doi: 10.1097/00006123-199804000-00126. [PMID: 9574657]
  • U Müller, D Y von Cramon, S Pollmann. D1- versus D2-receptor modulation of visuospatial working memory in humans. The Journal of neuroscience : the official journal of the Society for Neuroscience. 1998 Apr; 18(7):2720-8. doi: 10.1523/jneurosci.18-07-02720.1998. [PMID: 9502829]
  • W Thongsaard, S Pongsakorn, R Sudsuang, G W Bennett, D A Kendall, C A Marsden. Barakol, a natural anxiolytic, inhibits striatal dopamine release but off uptake in vitro. European journal of pharmacology. 1997 Jan; 319(2-3):157-64. doi: 10.1016/s0014-2999(96)00850-3. [PMID: 9042586]
  • P Barbier, A Colelli, R Maggio, D Bravi, G U Corsini. Pergolide binds tightly to dopamine D2 short receptors and induces receptor sequestration. Journal of neural transmission (Vienna, Austria : 1996). 1997; 104(8-9):867-74. doi: 10.1007/bf01285554. [PMID: 9451718]
  • L L Zou, Y Chen, Y Y Song, G Z Jin. Effect of (-)-stepholidine on serum prolactin level of female rats. Zhongguo yao li xue bao = Acta pharmacologica Sinica. 1996 Jul; 17(4):311-4. doi: NULL. [PMID: 9812710]
  • J I Sage, M H Mark. Drenching sweats as an off phenomenon in Parkinson's disease: treatment and relation to plasma levodopa profile. Annals of neurology. 1995 Jan; 37(1):120-2. doi: 10.1002/ana.410370124. [PMID: 7818245]
  • G Pezzoli, M Canesi, A Pesenti, C B Mariani. Pergolide mesylate in Parkinson's disease treatment. Journal of neural transmission. Supplementum. 1995; 45(?):203-12. doi: NULL. [PMID: 8748627]
  • K W Lange, W D Rausch, W Gsell, M Naumann, E Oestreicher, P Riederer. Neuroprotection by dopamine agonists. Journal of neural transmission. Supplementum. 1994; 43(?):183-201. doi: . [PMID: 7884400]
  • S O Ogren, J Lundström, L B Nilsson, M Widman. Dopamine D2 blocking activity and plasma concentrations of remoxipride and its main metabolites in the rat. Journal of neural transmission. General section. 1993; 93(3):187-203. doi: 10.1007/bf01244996. [PMID: 8217058]
  • R R Bowsher, J M Apathy, J A Compton, R L Wolen, K H Carlson, K A DeSante. Sensitive, specific radioimmunoassay for quantifying pergolide in plasma. Clinical chemistry. 1992 Oct; 38(10):1975-80. doi: 10.1093/clinchem/38.10.1975. [PMID: 1394981]
  • R W Fuller, H D Snoddy. Neuroendocrine evidence for antagonism of serotonin and dopamine receptors by olanzapine (LY170053), an antipsychotic drug candidate. Research communications in chemical pathology and pharmacology. 1992 Jul; 77(1):87-93. doi: NULL. [PMID: 1359615]
  • P D Williams, A Bendele, A Deldar, J McGrath, T Shetler, N Owen. General pharmacology of pergolide in animals. 2nd communication: gastrointestinal, renal and miscellaneous studies. Arzneimittel-Forschung. 1992 Jul; 42(7):891-5. doi: NULL. [PMID: 1418052]
  • H Pisarek, H Stepien, M Pawlikowski. Effect of mesulergine on prolactin secretion and dopamine D2 receptors-adaptive changes in diethylstilbestrol-induced hyperplasia of the rat anterior pituitary. Endocrine regulations. 1992 Mar; 26(1):17-22. doi: NULL. [PMID: 1421203]
  • J Buelke-Sam, I R Cohen, J P Tizzano, N V Owen. Developmental toxicity of the dopamine agonist pergolide mesylate in CD-1 mice. II: Perinatal and postnatal exposure. Neurotoxicology and teratology. 1991 May; 13(3):297-306. doi: 10.1016/0892-0362(91)90075-8. [PMID: 1886539]
  • S Rush, B Donahue, P Cooper, C Lee, M Persky, J Newall. Prolactin reduction after combined therapy for prolactin macroadenomas. Neurosurgery. 1991 Apr; 28(4):502-5. doi: 10.1097/00006123-199104000-00003. [PMID: 2034342]
  • M M Foreman, R W Fuller, M D Hynes, J S Gidda, C L Nichols, J M Schaus, E C Kornfeld, J A Clemens. Preclinical studies on quinelorane, a potent and highly selective D2-dopaminergic agonist. The Journal of pharmacology and experimental therapeutics. 1989 Jul; 250(1):227-35. doi: NULL. [PMID: 2526214]
  • R S Salah, D M Kuhn, M P Galloway. Dopamine autoreceptors modulate the phosphorylation of tyrosine hydroxylase in rat striatal slices. Journal of neurochemistry. 1989 May; 52(5):1517-22. doi: 10.1111/j.1471-4159.1989.tb09202.x. [PMID: 2565375]
  • I M de Mengido, D Becú-Villalobos, G Díaz, C Libertun. Chronic activation of dopamine receptors in the female infantile rat: effect on hypophyseal hormones and on the onset of puberty. Endocrinology. 1989 Feb; 124(2):746-53. doi: 10.1210/endo-124-2-746. [PMID: 2492218]
  • R S Rodger, W L Sheldon, M J Watson, J H Dewar, R Wilkinson, M K Ward, D N Kerr. Zinc deficiency and hyperprolactinaemia are not reversible causes of sexual dysfunction in uraemia. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 1989; 4(10):888-92. doi: 10.1093/ndt/4.10.888. [PMID: 2515494]
  • C M Gust, R W Fuller. Further characterization of tolerance to the corticosterone-elevating effect of pergolide in rats. Neuroscience letters. 1988 Nov; 93(2-3):307-11. doi: 10.1016/0304-3940(88)90100-0. [PMID: 2907374]
  • I Kitchen, M Kelly, M Turner. Dopamine receptor modulation of corticosterone secretion in neonatal and adult rats. The Journal of pharmacy and pharmacology. 1988 Aug; 40(8):580-1. doi: 10.1111/j.2042-7158.1988.tb05309.x. [PMID: 2907016]
  • E Jungmann, T Haak, P H Althoff, W Fassbinder, K Schöffling. Dopaminergic effects on kidney function and responsiveness of aldosterone, plasma renin activity, prolactin, catecholamines, and blood pressure to stimulation in patients with prolactinoma. Comparison of the efficacy of pergolide and bromocriptine therapy. Arzneimittel-Forschung. 1988 Feb; 38(2):296-300. doi: . [PMID: 3285838]
  • M L Cohen, R W Fuller, K D Kurz, C J Parli, N R Mason, D B Meyers, J K Smallwood, R E Toomey. Preclinical pharmacology of a new serotonergic receptor antagonist, LY281067. The Journal of pharmacology and experimental therapeutics. 1988 Jan; 244(1):106-12. doi: NULL. [PMID: 3335993]
  • J D Leander. Effects of specific D-1 and D-2 dopamine agonists (LY141865 and SKF-38393) and pergolide on urinary output of rats. Archives internationales de pharmacodynamie et de therapie. 1987 Oct; 289(2):290-5. doi: . [PMID: 2962555]
  • B S Jandhyala, M F Lokhandwala, S D Kivlighn, A F Ansari, M L De Feo. Intracisternal administration of pergolide, a dopamine receptor agonist, triggers the release of an inhibitor of ouabain-sensitive sodium, potassium-dependent adenosine triphosphatase and enhances vascular reactivity in anaesthetized dogs. Clinical science (London, England : 1979). 1987 Aug; 73(2):183-8. doi: 10.1042/cs0730183. [PMID: 2443297]
  • J Lorrain, E Donato Di Paola, F Lhoste, I Cavero. Effects of pergolide on the cardiovascular responses to sinoaortic deafferentation in dogs with intact or surgically decentralized adrenal glands. The Journal of pharmacology and experimental therapeutics. 1987 Jan; 240(1):288-93. doi: NULL. [PMID: 3806390]
  • R W Fuller, N R Mason. Flumezapine, an antagonist of central dopamine and serotonin receptors. Research communications in chemical pathology and pharmacology. 1986 Oct; 54(1):23-34. doi: NULL. [PMID: 2879325]
  • O A Kletzky, G A Shangold. Variability and selectivity of anterior pituitary response to dopamine agonists throughout the normal menstrual cycle. American journal of obstetrics and gynecology. 1986 Feb; 154(2):362-7. doi: 10.1016/0002-9378(86)90672-1. [PMID: 3080890]
  • J B Young, M A Brownjohn, C Chapman, M R Lee. The acute effects of pergolide in cyclical oedema. Pharmatherapeutica. 1986; 4(9):551-4. doi: NULL. [PMID: 3763649]
  • E Jungmann, P M Schumm-Draeger, C Timm, S Abdelhamid, K Schöffling. Human atrial natriuretic peptide (hANP) has no effect upon dopaminergic pathways: preliminary evidence in nude mice bearing heterotransplanted human CONN's adenoma tissue. Klinische Wochenschrift. 1986; 64 Suppl 6(?):47-9. doi: NULL. [PMID: 2948062]
  • I Cavero, J Lorrain, E D Di Paola, F Lhoste, B Payen, T Dennis, B Scatton. Pharmacological, hemodynamic and biochemical mechanisms involved in the blood pressure lowering effects of pergolide, in normotensive and hypertensive dogs. The Journal of pharmacology and experimental therapeutics. 1985 Dec; 235(3):798-809. doi: NULL. [PMID: 2934543]
  • R V Lloyd, K Schmidt, V Nath. Effects of pergolide on diethylstilbestrol-induced rat pituitary hyperplasia. The American journal of pathology. 1985 Dec; 121(3):486-95. doi: NULL. [PMID: 4073221]
  • B Corenblum. The medical treatment of the hypersecreting pituitary gland. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques. 1985 Aug; 12(3):243-50. doi: 10.1017/s0317167100047090. [PMID: 2996735]
  • D P Rose, M Gottardis. Interactions between estrogens, prolactin, and growth hormone on the growth of N-nitrosomethylurea-induced rat mammary tumors. Anticancer research. 1985 Jul; 5(4):397-402. doi: NULL. [PMID: 4037735]
  • A Grossman, P M Bouloux, R Loneragan, L H Rees, J A Wass, G M Besser. Comparison of the clinical activity of mesulergine and pergolide in the treatment of hyperprolactinaemia. Clinical endocrinology. 1985 May; 22(5):611-6. doi: 10.1111/j.1365-2265.1985.tb02996.x. [PMID: 4028459]
  • A Grossman, R Ross, M Charlesworth, C B Adams, J A Wass, I Doniach, G M Besser. The effect of dopamine agonist therapy on large functionless pituitary tumours. Clinical endocrinology. 1985 May; 22(5):679-86. doi: 10.1111/j.1365-2265.1985.tb03004.x. [PMID: 4028461]
  • K De Meirleir, L Baeyens, M L'Hermite, M L'Hermite-Balériaux, J Olbrecht, W Holmann. Pergolide mesylate inhibits exercise-induced prolactin release in man. Fertility and sterility. 1985 Apr; 43(4):628-31. doi: 10.1016/s0015-0282(16)48508-0. [PMID: 3987929]
  • B W Scheithauer, R V Randall, E R Laws, K T Kovacs, E Horvath, M D Whitaker. Prolactin cell carcinoma of the pituitary. Clinicopathologic, immunohistochemical, and ultrastructural study of a case with cranial and extracranial metastases. Cancer. 1985 Feb; 55(3):598-604. doi: 10.1002/1097-0142(19850201)55:3<598::aid-cncr2820550320>3.0.co;2-s. [PMID: 3965110]
  • R W Fuller, H D Snoddy. Central dopamine receptors mediating pergolide-induced elevation of serum corticosterone in rats. Characterization by the use of antagonists. Neuropharmacology. 1984 Dec; 23(12A):1389-94. doi: 10.1016/0028-3908(84)90078-9. [PMID: 6527743]
  • M Da Prada, H H Keller, L Pieri, R Kettler, W E Haefely. The pharmacology of Parkinson's disease: basic aspects and recent advances. Experientia. 1984 Nov; 40(11):1165-72. doi: 10.1007/bf01946641. [PMID: 6437857]
  • S P Arnerić, S A Chow, J P Long, L J Fischer. Inhibition of insulin release from rat pancreatic islets by drugs that are analogues of dopamine. Diabetes. 1984 Sep; 33(9):888-93. doi: 10.2337/diab.33.9.888. [PMID: 6147289]
  • D G Johnston, K Hall, P Kendall-Taylor, D Patrick, M Watson, D B Cook. Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. Studies with high-definition computerised tomography. Lancet (London, England). 1984 Jul; 2(8396):187-92. doi: 10.1016/s0140-6736(84)90480-x. [PMID: 6146751]
  • S P Arnerić, S A Chow, J P Long, L J Fischer. Dopamine analog-induced hyperglycemia in rats: involvement of the adrenal medulla and the endocrine pancreas. The Journal of pharmacology and experimental therapeutics. 1984 Mar; 228(3):551-9. doi: . [PMID: 6142939]
  • I Cavero, F Lefevre-Borg, F Lhoste, C Sabatier, C Richer, J F Giudicelli. Pharmacological, hemodynamic and autonomic nervous system mechanisms responsible for the blood pressure and heart rate lowering effects of pergolide in rats. The Journal of pharmacology and experimental therapeutics. 1984 Mar; 228(3):779-91. doi: NULL. [PMID: 6707926]
  • K Sriwatanakul, K McCormick, P Woolf. Thyrotropin (TSH)-induced hyperthyroidism: response of TSH to dopamine and its agonists. The Journal of clinical endocrinology and metabolism. 1984 Feb; 58(2):255-61. doi: 10.1210/jcem-58-2-255. [PMID: 6420433]
  • R W Fuller, H D Snoddy. Molindone: higher doses needed to block pergolide-induced elevation of serum corticosterone than to elevate dopamine metabolites in brain. Life sciences. 1983 Dec; 33(23):2357-61. doi: 10.1016/0024-3205(83)90270-9. [PMID: 6645804]
  • P Kendall-Taylor, G Upstill-Goddard, D Cook. Longterm pergolide treatment of acromegaly. Clinical endocrinology. 1983 Dec; 19(6):711-9. doi: 10.1111/j.1365-2265.1983.tb00049.x. [PMID: 6652932]
  • D L Kleinberg, A E Boyd, S Wardlaw, A G Frantz, A George, N Bryan, S Hilal, J Greising, D Hamilton, T Seltzer, C J Sommers. Pergolide for the treatment of pituitary tumors secreting prolactin or growth hormone. The New England journal of medicine. 1983 Sep; 309(12):704-9. doi: 10.1056/nejm198309223091205. [PMID: 6888442]
  • D P Rose, M Gottardis, J J Noonan. Rat mammary carcinoma regressions during suppression of serum growth hormone and prolactin. Anticancer research. 1983 Sep; 3(5):323-5. doi: . [PMID: 6139974]
  • D P Rose, K G Mountjoy. Influence of thyroidectomy and prolactin suppression on the growth of N-nitrosomethylurea-induced rat mammary carcinomas. Cancer research. 1983 Jun; 43(6):2588-91. doi: NULL. [PMID: 6850579]
  • B L Horowitz, D J Hamilton, C J Sommers, R N Bryan, A E Boyd. Effect of bromocriptine and pergolide on pituitary tumor size and serum prolactin. AJNR. American journal of neuroradiology. 1983 May; 4(3):415-7. doi: . [PMID: 6410759]
  • S Franks, P M Horrocks, S S Lynch, W R Butt, D R London. Effectiveness of pergolide mesylate in long term treatment of hyperprolactinaemia. British medical journal (Clinical research ed.). 1983 Apr; 286(6372):1177-9. doi: 10.1136/bmj.286.6372.1177. [PMID: 6404378]
  • L Nedelec, A Pierdet, P Fauveau, C Euvrard, L Proulx-Ferland, C Dumont, F Labrie, J R Boissier. Synthesis and central dopaminergic activities of (+/-)-hexahydro-7H-indolo[3,4-gh][1,4]benzoxazine derivatives [(+/-)-9-oxaergolines]. Journal of medicinal chemistry. 1983 Apr; 26(4):522-7. doi: 10.1021/jm00358a012. [PMID: 6834383]
  • R W Fuller, H D Snoddy, N R Mason, J A Clemens, K G Bemis. Elevation of serum corticosterone in rats by dopamine agonists related in structure to pergolide. Neuroendocrinology. 1983; 36(4):285-90. doi: 10.1159/000123469. [PMID: 6866215]
  • R W Fuller, J A Clemens, M D Hynes. Degree of selectivity of pergolide as an agonist at presynaptic versus postsynaptic dopamine receptors: implications for prevention or treatment of tardive dyskinesia. Journal of clinical psychopharmacology. 1982 Dec; 2(6):371-5. doi: . [PMID: 7174859]
  • R W Fuller, H D Snoddy. Serum corticosterone elevation by pergolide in rats: prevention of tolerance development by spiperone. The Journal of pharmacy and pharmacology. 1982 Sep; 34(9):607-8. doi: 10.1111/j.2042-7158.1982.tb04808.x. [PMID: 6127394]
  • P Kendall-Taylor, K Hall, D G Johnston, R W Prescott. Reduction in size of prolactin-secreting tumours in men treated with pergolide. British medical journal (Clinical research ed.). 1982 Aug; 285(6340):465-7. doi: 10.1136/bmj.285.6340.465. [PMID: 6809126]